Genomics in drug discovery: The best things come to those who wait

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 3, 2008, Pages 303-310

  Bansal, A T ^a   Barnes, M R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Causal inference; Data integration; Drug discovery; Genetic association; Pharmacogenetics; RNAi; Sequencing; Transgenic

Indexed keywords

CARBAMAZEPINE; LAPATINIB; RAPAMYCIN; SEROTONIN 3 ANTAGONIST; TRASTUZUMAB;

AUTOMATION; CROHN DISEASE; ELECTRONICS; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENOME; GENOMICS; HUMAN; NONHUMAN; PHARMACOGENETICS; REVIEW; RNA INTERFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRANSGENICS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; DIFFUSION OF INNOVATION; DRUG DESIGN; EPIGENESIS, GENETIC; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOMICS; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; RNA INTERFERENCE; TECHNOLOGY, PHARMACEUTICAL;

EID: 42449143066     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. The FDA's Critical Path Initiative: US Food & Drug Administration, Rockville, MD, USA. www.fda.gov/oc/initiatives/criticalpath •• Includes an important position statement by the FDA demonstrating the positive view that the FDA leadership holds of genomic approaches to drug discovery.
2. Biotechnology Entrez Genome Project: National Center for Biotechnology Information, Bethesda, MD, USA. www.ncbi.nlm.nih.gov/genomes/ leuks.cgi
3. Dickinson H, Moritz K, Wintour EM, Walker DW, Kett MM: A comparative study of renal function in the desert-adapted spiny mouse and the laboratory-adapted C57BL/6 mouse: Response to dietary salt load. Am J Physiol - Renal Physiol (2007) 293(4):F1093-F1098.
4. Bentley DR: Whole-genome re-sequencing. Curr Opin Genet Dev (2006) 16(6):545-552. • Provides an excellent background review of short-read sequencing technologies.
5. Instructions for submitting a proposal for the sequencing of a new target genome: National Human Genome Research Institute, Bethesda, MD, USA. www.genome.gov/11509736
6. Sundquist A, Ronaghi M, Tang H, Pevzner P, Batzoglou S: Whole-genome sequencing and assembly with high-throughput, short-read technologies. PLoS ONE (2007) 2(5):e484.
7. Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, Caldwell CW, Shi H: Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res (2007) 67(18):8511-8518.
8. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, Chen X, Vilaythong JN, Issa JP: Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res (2007) 67(23):11335-11343.
9. James Watson's personal genome sequence: Human Genome Sequencing Center, Houston, TX, USA. jimwatsonsequence.cshl.edu/
10. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y et al: The diploid genome sequence of an individual human. PLoS Biol (2007) 5(10):e254.
11. Kaiser J: Breakthrough of the year. It's all about me. Science (2007) 318(5858):1843.
12. Hunter DJ, Khoury MJ, Drazen JM: Letting the genome out of the bottle - Will we get our wish? N Engl J Med (2008) 358(2):105-107.
13. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S et al: A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 449(7164):851-861. •• Provides a key publication which comprehensively characterizes the patterns of genetic variation in four human population samples.
14. Bentley D, Brown MA, Cardon LR, Caulfield M, Clayton DG, Compston A, Craddock N, Deloukas P, Donnelly P, Farrall M, Gough SCL et al: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 447(7145):661-678. •• Describes a landmark study in the field of human disease genetics. Patient collections for seven common diseases were scanned for common variants that predispose to disease susceptibility.
15. Roeder K, Bacanu SA, Wasserman L, Devlin B: Using linkage genome scans to improve power of association in genome scans. Am J Hum Genet (2006) 78(2):243-252.
16. Pe'er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, Daly MJ: Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat Genet (2006) 38(6): 663-667. • Provides an excellent evaluation of the potential pitfalls and benefits of fixed SNP marker panels for genome-wide association studies.
17. Chen GK, Witte JS: Enriching the analysis of genomewide association studies with hierarchical modeling. Am J Hum Genet (2007) 81(2):397-404.
18. Wang K, Li M, Bucan M: Pathway-based approaches for analysis of genomewide association studies. Am J Hum Genet (2007) 81(6):1278-1283.
19. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D, Drummond H et al: Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet (2007) 39(7):830-832.
20. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ: Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 6(4):304-312.
21. Holbrook JD, Sanseau P: Drug discovery and computational evolutionary analysis. Drug Disc Today (2007) 12(19-20):826-832. • Provides a drug discovery-centric view of Darwinian selection analysis.
22. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, Xie X, Byrne EH, McCarroll SA, Gaudet R, Schaffner SF et al: Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 449(7164):913-918. •• Describes a study that demonstrates the power of the HapMap as a research dataset. Taking information on variation in four study populations, signatures of Darwinian selection were successfully detected.
23. Crespi B, Summers K, Dorus S: Adaptive evolution of genes underlying schizophrenia. Proc Biol Sci (2007) 274(1627):2801-2810.
24. Collins FS, Rossant J, Wurst W: A mouse for all reasons. Cell (2007) 128(1):9-13.
25. Mouse Genome Informatics: The Jackson Laboratory, Bar Harbor, ME, USA (2008). www.informatics.jax.org
26. Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 6(7):556-568.
27. Janas J, Skowronski J, Van Aelst L: Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol (2006) 406:593-605.
28. Klinghoffer RA, Roberts B, Annis J, Frazier J, Lewis P, Linsley PS, Cleary MA: An optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-5 inhibitor sensitivity. Assay Drug Dev Technologies (2008) 6(1):105-119.
29. Brem RB, Yvert G, Clinton R, Kruglyak L: Genetic dissection of transcriptional regulation in budding yeast. Science (2002) 296(5568):752-755.
30. Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, Hsu HC, Mountz JD, Baldwin NE, Langston MA, Threadgill DW et al: Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat Genet (2005) 37(3):233-242.
31. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, Taylor J, Burnett E, Gut I, Farrall M, Lathrop GM et al: A genome-wide association study of global gene expression. Nat Genet (2007) 39(10):1202-1207. •• Describes an excellent study of the impact of variation on gene expression in lymphoblast cell lines. All the data in the study are available to download and analyze using a stand-alone tool.
32. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C, Ingle CE, Dunning M, Flicek P, Koller D, Montgomery S et al: Population genomics of human gene expression. Nat Genet (2007) 39(10):1217-1224.
33. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L, Kaleem M, Leung D, Bryden L, Nath P, Zismann VL et al: A survey of genetic human cortical gene expression. Nat Genet (2007) 39(12):1494-1499.
34. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, Vermeire S, Dewit O, de Vos M, Dixon A, Demarche B et al: Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 3(4):e58.
35. Alberts R, Terpstra P, Li Y, Breitling R, Nap JP, Jansen RC: Sequence polymorphisms cause many false cis eQTLs. PLoS ONE (2007) 2(7):e622.
36. Sieberts SK, Schadt EE: Moving toward a system genetics view of disease. Mamm Genome (2007) 18(6-7):389-401.
37. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 66(3):1630-1639.
38. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, Guchelaar HJ: Translating pharmacogenomics: Challenges on the road to the clinic. PLoS Med (2007) 4(8):e209.
39. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics Genomics (2006) 16(4):297-306.
40. Woodcock J, Woosley R: The FDA Critical Path Initiative and its influence on new drug development. Annu Rev Med (2008) 59: 1-12. •• Provides a review of the FDA Critical Path Initiative and also highlights some of the progress to date toward achieving the goals of the Initiative.
41. The Orphan Drug Act: US Food & Drug Administration, Rockville, MD, USA. www.fda.gov/orphan/oda.htm